证券代码：688389 证券简称：普门科技 公告编号：2026-021 深圳普门科技股份有限公司 关于2022年股票期权激励计划2026年第一季度 自主行权结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●本次行权数量： 深圳普门科技股份有限公司（以下简称"公司"）2022年股票期权激励计划 （以下简称"2022年激励计划"）首次授予股票期权第三个行权期可行权数量为 3,164,800份，行权有效期为2025年6月30日至2026年5月8日。2026年1月1日至2026 年3月31日期间，累计行权并完成股份过户登记数量为0股。 3. 2022年4月17日至2022年4月26日，公司对本激励计划首次授予的激励对象 的姓名和职务在公司内部进行公示。截至公示期届满，公司监事会未收到任何人 对本次激励对象提出的异议。2022年4月28日，公司在上海证券交易所网站 （www.sse.com.cn）披露了《公司监事会关于公司2022年激励计划激励对象名单 的公示情况说明及核查意见》（公告编号：2022-02 ...

二、本次限制行权期为2026年4月8日至2026年4月22日，在此期间全部激励 对象将限制行权。 三、公司将按照有关规定通过自主行权主办券商国信证券股份有限公司及时 向中国证券登记结算有限责任公司上海分公司申请办理限制行权相关事宜。 特此公告。 证券代码：688389 证券简称：普门科技 公告编号：2026-022 深圳普门科技股份有限公司 关于2022年股票期权激励计划限制行权期间的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司股权激励管理办法》《深圳普门科技股份有限公司2022年股 票期权激励计划（草案）》及中国证券登记结算有限责任公司上海分公司关于股 票期权自主行权的相关规定，并结合深圳普门科技股份有限公司（以下简称"公 司"）2025年年度报告、2026年第一季度报告的披露工作计划，现对公司2022 年股票期权激励计划的限制行权时间公告如下： 深圳普门科技股份有限公司董事会 2026年4月2日 1 / 1 一、公司处于行权期的股票期权激励计划情况如下： 计划名称 行权期 行权起止日期 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [4]. Core Insights - The pharmaceutical and biotechnology sector is experiencing a significant data catalyst window with the upcoming AACR annual meeting, which is expected to enhance the global competitiveness of Chinese innovative drugs [5]. - The industry index declined by 1.26%, outperforming the CSI 300 index, with notable gains in medical research outsourcing and chemical preparations [2][13]. - The overall PE ratio for the pharmaceutical and biotechnology industry is 29.30x, down from 30.34x, indicating a valuation decline below the average [17]. Industry Review - The report highlights that the innovative drug sector is currently the core focus, supported by favorable domestic policies such as the NMPA's "Spring Rain Action" to promote clinical innovation in medical devices [4][5]. - The total amount of innovative drug licensing transactions in China exceeded $60 billion in the first three months of 2026, indicating a strong global recognition of Chinese innovative drug assets [5]. - The report suggests focusing on companies with core technology platforms and differentiated pipeline layouts, particularly those expected to achieve positive catalysts at major academic conferences like AACR [5]. Important Industry News - The NMPA has initiated a three-year "Spring Rain Action" to support the transformation of clinical innovation in medical devices [21][26]. - Johnson & Johnson's oral IL-23R antagonist "Icotrokinra" has been approved by the FDA, marking it as the first of its kind globally [41]. - Novo Nordisk's weekly insulin "Awiqli" has received FDA approval, providing a new treatment option for type 2 diabetes patients [44]. - AstraZeneca and Amgen's TSLP monoclonal antibody "Tezepelumab" has been approved in China, making it the first of its kind domestically [46]. Company Dynamics - Novartis plans to invest over 3.3 billion RMB in China to enhance its R&D, production, and operational capabilities [48].

证券代码：688389 证券简称：普门科技 公告编号：2026-020 深圳普门科技股份有限公司 关于 2026 年股票期权激励计划授予登记完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 根据 2026 年 2 月 5 日召开的深圳普门科技股份有限公司（以下简称"公司" 或"普门科技"）2026 年第一次临时股东会的授权，公司于 2026 年 2 月 5 日召 开第三届董事会第二十二次会议，审议通过了《关于向激励对象授予股票期权的 议案》。根据中国证监会《上市公司股权激励管理办法》以及上海证券交易所、 中国证券登记结算有限责任公司上海分公司有关规定，公司完成了 2026 年股票 期权激励计划（以下简称"本激励计划"）的授予登记工作，现将有关情况公告 如下： 一、本激励计划已履行的决策程序和信息披露情况 1. 2026 年 1 月 19 日，公司召开第三届董事会薪酬与考核委员会第十二次 会议，审议通过《关于〈公司 2026 年股票期权激励计划（草案）〉及其摘要的 议案》《关于〈公司 2026 年股 ...

证券代码：688389 证券简称：普门科技 公告编号：2026-019 新产品取得注册证进一步丰富了公司体外诊断产品矩阵，有助于提升公司市 场综合竞争力，对未来市场拓展以及公司未来的经营产生积极影响。 三、风险提示 上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后 的实际销售情况取决于未来市场的推广效果、配套试剂的获证情况，目前尚无法 深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体情况如下： | 产品名称 | 注册 | 注册证 | 注册证 | 适用范围 | | --- | --- | --- | --- | --- | | | 分类 | 编号 | 有效期至 | | | | | | | 该产品采用散射比浊法、透射比浊 法和比色法，与适配试剂配合使 | | | | | | 用，在临床上用于对来源于人体的 | | | | ...

Summary of the Conference Call for Pumen Technology Company Overview - **Company**: Pumen Technology - **Industry**: In Vitro Diagnostics (IVD) and Consumer Health Key Points Industry and Market Dynamics - Domestic IVD business policy impacts are expected to clear up, with a market turnaround anticipated in the second half of 2026 [2][5] - The IVD industry is projected to see growth in testing volumes due to aging population trends, despite ongoing price pressures [6] Product Lines and Growth Strategies - **Core Product Lines**: CRP, Glycated Hemoglobin, and Electrochemiluminescence are expected to stabilize and recover through grassroots screening and high-end replacements [2] - **Overseas Business**: Targeting a growth rate of ≥20% annually, with overseas revenue now exceeding 40% of total income [2][7] - **Consumer Health**: Focus on skin aesthetics and ToC health, with expectations for over 50% growth in the aesthetics segment by 2026 [2][5] Financial Performance and Projections - The company aims to achieve a sales target of over 100 million RMB in the ToC business by 2026, with a doubling of revenue expected in 2025 [2][4] - The consumer health business is projected to turn profitable in 2025 after significant growth [16] Strategic Initiatives - **Cost Management**: Emphasis on self-sourcing core materials to alleviate cost pressures due to healthcare cost control [2][5] - **International Expansion**: Establishing subsidiaries in key markets (e.g., Russia, India, Mexico) to mitigate risks associated with agency limitations and payment issues [2][7][10] Technological Integration - AI technologies are deeply integrated into business lines, with projects in AI interpretation of chromatograms and thrombus prevention systems [3][17] - The company is exploring brain-machine interface applications in home rehabilitation [3][17] Regulatory and Market Challenges - Anticipated regulatory changes in the domestic IVD market, including payment reforms and collection of testing packages, are expected to impact growth in 2025 [5] - The company is cautious about the medical aesthetics market, which is currently undergoing adjustments due to regulatory changes [13] Future Product Development - New product lines in endoscopy and aesthetics are in the registration phase, with expectations for market entry in 1-2 years [12] - The company is focusing on high-value consumables in its aesthetics product line, with significant potential for products like ultrasound knives and gold microneedles [14] Sales and Distribution Strategy - The company employs a mixed sales strategy, combining direct sales for large clients with authorized distribution for others to maintain market stability [14] Online Business Strategy - The consumer health business has seen rapid growth, with a focus on effective product development rather than gimmicky offerings [15][16] - The online business is expected to achieve profitability in 2025, with clear profit targets set for 2026 [16] Conclusion - Pumen Technology is strategically positioned for growth in both domestic and international markets, with a strong focus on innovation, cost management, and regulatory compliance. The integration of AI and a robust product pipeline in consumer health and aesthetics are key components of its future success.

证券代码：688389 证券简称：普门科技 公告编号：2026-018 深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： 二、对公司的影响 维生素 D 具有促进小肠钙吸收，促进肾小管对钙、磷的重吸收，调节血钙 平衡，参与多种骨代谢途径等多重作用。及时了解人体的维生素 D 状态，可以 为个体提供补充维生素 D 提供参考。 本次取得注册证的试剂盒，采用免疫荧光层析法，应用双抗体夹心法原理， 具备较高的灵敏度、精密度等性能，与公司干式荧光免疫分析仪配合使用可以计 算出血液样本中 25-OH VD 的含量。该注册证的取得，进一步丰富和完善了公司 免疫荧光层析技术平台的检测试剂菜单，提升公司在 POCT（即时检测）领域的 市场竞争力。 三、风险提示 上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后 的 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： 证券代码：688389 证券简称：普门科技 公告编号：2026-017 深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 剂注册证。 三、风险提示 上述注册证的取得仅代表公司相关产品获得国内市场准入资格，产品上市后 的实际销售情况取决于未来市场的推广效果，目前尚无法预测上述产品对公司未 来业绩的具体影响。 敬请投资者理性投资，注意投资风险。 特此公告。 二、对公司的影响 促红细胞生成素（Erythropoietin，EPO）又称红细胞刺激因子，是一种内源 性酸性糖蛋白激素。EPO 能显著刺激红细胞的增殖、存活，促进造血，并且具 有促进血管生成、脑保护、肾脏保护、心脏保护、调节代谢、调节呼吸、保护消 化系统和生殖系统等作用。EPO 的分泌不足与某些形式的贫血有关，包括肾功 能衰竭贫血和终末期肾脏疾病贫血，而其它 ...

Core Viewpoint - Pumen Technology (688389.SH) reported a decline in revenue and net profit for the fiscal year 2025, attributed to domestic healthcare payment reforms and price adjustments in some products [1] Financial Performance - The company achieved total operating revenue of 1.038 billion yuan, a year-on-year decrease of 9.60% [1] - The net profit attributable to the parent company was 186 million yuan, down 46.12% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 166 million yuan, a decrease of 49.28% year-on-year [1] Business Operations - Domestic business revenue declined compared to the same period last year due to industry policy impacts [1] - International marketing business showed stable growth, with ongoing efforts in regional coverage, localized services, and market access [1] - The company remains focused on its core business strategy, emphasizing in vitro diagnostics, clinical medicine, dermatology aesthetics, and consumer health markets [1] - Continuous investment in R&D and marketing is maintained to enrich product offerings and expand market reach [1]

Group 1 - The core viewpoint of the article is that Pumen Technology announced its financial projections for the year 2025, indicating significant revenue and profit expectations [2] Group 2 - The company expects to achieve a total operating revenue of 1,037.83 million yuan in 2025 [2] - The projected net profit attributable to the parent company's shareholders is 186.09 million yuan for the same year [2]